113 related articles for article (PubMed ID: 32371123)
1. Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study.
van der Meulen M; Bakunina K; Nijland M; Minnema MC; Cull G; Stevens WBC; Baars JW; Mason KD; Beeker A; Beijert M; Taphoorn MJB; van den Bent MJ; Issa S; Doorduijn JK; Bromberg JEC; Dirven L
Ann Oncol; 2020 Aug; 31(8):1046-1055. PubMed ID: 32371123
[TBL] [Abstract][Full Text] [Related]
2. Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.
Bromberg JEC; Issa S; van der Holt B; van der Meulen M; Dirven L; Minnema MC; Seute T; Durian M; Cull G; van der Poel MWM; Stevens WBC; Zijlstra JM; Brandsma D; Nijland M; Mason KD; Beeker A; Abrahamse-Testroote MCJ; van den Bent MJ; de Jong D; Doorduijn JK
Neuro Oncol; 2024 Apr; 26(4):724-734. PubMed ID: 38037691
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
4. Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial.
van der Meulen M; Dirven L; Habets EJJ; Bakunina K; Smits M; Achterberg HC; Seute T; Cull G; Schouten H; Zijlstra JM; Brandsma D; Enting RH; Beijert M; Taphoorn MJB; van den Bent MJ; Issa S; Doorduijn JK; Bromberg JEC
Neuro Oncol; 2021 Aug; 23(8):1315-1326. PubMed ID: 33560442
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK
Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772
[TBL] [Abstract][Full Text] [Related]
6. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
Dirven L; van den Bent MJ; Bottomley A; van der Meer N; van der Holt B; Vos MJ; Walenkamp AM; Beerepoot LV; Hanse MC; Reijneveld JC; Otten A; de Vos FY; Smits M; Bromberg JE; Taal W; Taphoorn MJ;
Eur J Cancer; 2015 Jul; 51(10):1321-30. PubMed ID: 25899986
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
Coens C; Suciu S; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Bottomley A; Kotapati S; de Pril V; Testori A; Eggermont AMM
Lancet Oncol; 2017 Mar; 18(3):393-403. PubMed ID: 28162999
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
9. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
[TBL] [Abstract][Full Text] [Related]
10. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial.
Noordman BJ; Verdam MGE; Lagarde SM; Shapiro J; Hulshof MCCM; van Berge Henegouwen MI; Wijnhoven BPL; Nieuwenhuijzen GAP; Bonenkamp JJ; Cuesta MA; Plukker JTM; Spillenaar Bilgen EJ; Steyerberg EW; van der Gaast A; Sprangers MAG; van Lanschot JJB;
Ann Oncol; 2018 Feb; 29(2):445-451. PubMed ID: 29126244
[TBL] [Abstract][Full Text] [Related]
11. Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
Clement PMJ; Dirven L; Eoli M; Sepulveda-Sanchez JM; Walenkamp AME; Frenel JS; Franceschi E; Weller M; Chinot O; De Vos FYFL; Whenham N; Sanghera P; Looman J; Kundu MG; Peter de Geus J; Nuyens S; Spruyt M; Gorlia T; Coens C; Golfinopoulos V; Reijneveld JC; van den Bent MJ
Eur J Cancer; 2021 Apr; 147():1-12. PubMed ID: 33601293
[TBL] [Abstract][Full Text] [Related]
12. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results.
Soffietti R; Kocher M; Abacioglu UM; Villa S; Fauchon F; Baumert BG; Fariselli L; Tzuk-Shina T; Kortmann RD; Carrie C; Ben Hassel M; Kouri M; Valeinis E; van den Berge D; Mueller RP; Tridello G; Collette L; Bottomley A
J Clin Oncol; 2013 Jan; 31(1):65-72. PubMed ID: 23213105
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide.
Minniti G; Scaringi C; Baldoni A; Lanzetta G; De Sanctis V; Esposito V; Enrici RM
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):285-91. PubMed ID: 23642624
[TBL] [Abstract][Full Text] [Related]
14. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.
Heutte N; Flechtner HH; Mounier N; Mellink WA; Meerwaldt JH; Eghbali H; van't Veer MB; Noordijk EM; Kluin-Nelemans JC; Lampka E; Thomas J; Lugtenburg PJ; Viterbo L; Carde P; Hagenbeek A; van der Maazen RW; Smit WG; Brice P; van Marwijk Kooy M; Baars JW; Poortmans P; Tirelli U; Leeksma OC; Tomsic R; Feugier P; Salles G; Gabarre J; Kersten MJ; Van Den Neste E; Creemers GJ; Gaillard I; Meijnders P; Tertian G; Reman O; Muller HP; Troncy J; Blanc M; Schroyens W; Voogt PJ; Wijermans P; Rieux C; Fermé C; Henry-Amar M;
Lancet Oncol; 2009 Dec; 10(12):1160-70. PubMed ID: 19828373
[TBL] [Abstract][Full Text] [Related]
15. Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
Burke JM; van der Jagt RH; Kahl BS; Wood P; Hawkins TE; MacDonald D; Hertzberg M; Simpson D; Craig M; Kolibaba K; Issa S; Munteanu M; Victor TW; Flinn IW
Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):182-190.e1. PubMed ID: 26875824
[TBL] [Abstract][Full Text] [Related]
16. Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033-26033.
Dirven L; Reijneveld JC; Taphoorn MJB; Coens C; El-Badawy SA; Tzuk-Shina T; Bravo-Marques J; Back M; Stalpers LJA; Stupp R; Baumert BG; Seidel C
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):90-100. PubMed ID: 30716525
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer.
Koole SN; Kieffer JM; K Sikorska ; Schagen van Leeuwen JH; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; van Ham MAPC; Aalbers AG; Verwaal VJ; Van de Vijver KK; Sonke GS; van Driel WJ; Aaronson NK
Eur J Surg Oncol; 2021 Jan; 47(1):101-107. PubMed ID: 31128948
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Taphoorn MJ; Stupp R; Coens C; Osoba D; Kortmann R; van den Bent MJ; Mason W; Mirimanoff RO; Baumert BG; Eisenhauer E; Forsyth P; Bottomley A; ; ;
Lancet Oncol; 2005 Dec; 6(12):937-44. PubMed ID: 16321761
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091).
Reijneveld JC; Machingura A; Coens C; Taphoorn MJB; Taal W; Clement PM; Idbaih A; de Vos FYF; Klein M; Wick W; Mulholland PJ; Lewis J; Golfinopoulos V; Ghislain I; Bottomley A; van den Bent MJ;
Eur J Cancer; 2023 Sep; 190():112946. PubMed ID: 37453240
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
